Partial maturation: An immune-evasion strategy of dengue virus?

Trends in Microbiology

Volumn 19, Issue 5, 2011, Pages 248-254

  Rodenhuis Zybert, Izabela A ^a   Wilschut, Jan ^a   Smit, Jolanda M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DENGUE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; CROSS REACTION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE SEVERITY; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; MOLECULAR EVOLUTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SECONDARY INFECTION; VIRION; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS MORPHOGENESIS; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WILD TYPE;

DENGUE VIRUS; HUMANS; IMMUNE EVASION; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRAL PROTEINS;

DENGUE VIRUS; FLAVIVIRUS;

EID: 79955464838     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2011.02.002     Document Type: Review

References (78)

1. Gubler D.J. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found. Symp. 2006, 277:3-16.
2. Kliks S.C., et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 1988, 38:411-419.
3. Simmons C.P., et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 2007, 196:416-424.
4. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002, 10:100-103.
5. Guzman M.G., et al. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 2002, 6:118-124.
6. Sierra B., et al. HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum. Immunol. 2007, 68:531-540.
7. Thisyakorn U., Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. Clin. Infect. Dis. 1993, 16:295-297.
8. Thomas S.J., et al. Dengue epidemiology: virus epidemiology, ecology, and emergence. Adv. Virus Res. 2003, 61:235-289.
9. Vaughn D.W., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181:2-9.
10. Wang W.K., et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 2003, 305:330-338.
11. Wang W.K., et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin. Infect. Dis. 2006, 43:1023-1030.
12. Libraty D.H., et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 2002, 186:1165-1168.
13. Halstead S.B. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med. 1970, 42:350-362.
14. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv.Virus Res. 2003, 60:421-467.
15. Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Adv.Virus Res. 2003, 59:23-61.
16. Heinz F.X., Allison S.L. Flavivirus structure and membrane fusion. Adv.Virus Res. 2003, 59:63-97.
17. Perera R., Kuhn R.J. Structural proteomics of dengue virus. Curr. Opin. Microbiol. 2008, 11:369-377.
18. Perera R., et al. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res. 2008, 80:11-22.
19. Zhang W., et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 2003, 10:907-912.
20. Krishnan M.N., et al. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J. Virol. 2007, 81:4881-4885.
21. van der Schaar H.M., et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 2007, 81:12019-12028.
22. van der Schaar H.M., et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog. 2008, 4:e1000244.
23. Harris E., et al. Molecular biology of flaviviruses. Novartis Found. Sym. 2006, 277:23-39.
24. Welsch S., et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 2009, 5:365-375.
25. Zhang Y., et al. Structures of immature flavivirus particles. EMBO J. 2003, 22:2604-2613.
26. Li L., et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319:1830-1834.
27. Rodenhuis-Zybert I.A., et al. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol. Life Sci. 2010, 67:2773-2786.
28. Yu I.M., et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008, 319:1834-1837.
29. Stadler K., et al. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 1997, 71:8475-8481.
30. Zybert I.A., et al. Functional importance of dengue virus maturation: infectious properties of immature virions. J. Gen.Virol. 2008, 89:3047-3051.
31. Zheng A., et al. In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions. PLoS Pathog. 2010, 6:e1001157.
32. Keelapang P., et al. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 2004, 78:2367-2381.
33. Randolph V.B., et al. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990, 174:450-458.
34. Moesker B., et al. Characterization of the functional requirements of West Nile virus membrane fusion. J. Gen.Virol. 2010, 91:389-393.
35. Elshuber S., et al. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 2003, 84:183-191.
36. Chang G.J., et al. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 2003, 306:170-180.
37. Falconar A.K. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch.Virol. 1999, 144:2313-2330.
38. He R.T., et al. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol. 1995, 45:451-461.
39. Henchal E.A., et al. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 1985, 34:162-169.
40. Junjhon J., et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J. Virol. 2008, 82:10776-10791.
41. Junjhon J., et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 2010, 84:8353-8358.
42. Murray J.M., et al. Processing of the dengue virus type 2 proteins prM and C-prM. J. Gen.Virol. 1993, 74:175-182.
43. Pryor M.J., et al. Histidine 39 in the dengue virus type 2M protein has an important role in virus assembly. J. Gen. Virol. 2004, 85:3627-3636.
44. Purdy D.E., Chang G.J. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology 2005, 333:239-250.
45. Roehrig J.T., et al. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246:317-328.
46. Heinz F.X., et al. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 1994, 198:109-117.
47. Cherrier M.V., et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009, 28:3269-3276.
48. Schmidt A.C. Response to dengue fever - the good, the bad, and the ugly?. N. Engl. J. Med. 2010, 363:484-487.
49. Oliphant T., Diamond M.S. The molecular basis of antibody-mediated neutralization of West Nile virus. Expert Opin. Biol. Ther. 2007, 7:885-892.
50. van der Schaar H.M., et al. Role of antibodies in controlling dengue virus infection. Immunobiology 2009, 7:613-629.
51. Beltramello M., et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8:271-283.
52. Cardosa M.J., et al. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol. 2002, 2:9.
53. Dejnirattisai W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328:745-748.
54. Se-Thoe S.Y., et al. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J. Med. Virol. 1999, 57:322-330.
55. Lai C.Y., et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 2008, 82:6631-6643.
56. Shrestha B., et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6:e1000823.
57. Sukupolvi-Petty S., et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 2010, 84:9227-9239.
58. Gromowski G.D., Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 2007, 366:349-360.
59. Matsuda T., et al. Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J. Gen.Virol. 2005, 86:1055-1065.
60. Lu M.Y., Liao F. Interferon-stimulated gene ISG12b2 is localized to the inner mitochondrial membrane and mediates virus-induced cell death 2. Cell Death Differ. 2010, 10.1038/cdd.2010.160.
61. Klomporn P., et al. Dengue infection of monocytic cells activates ER stress pathways, but apoptosis is induced through both extrinsic and intrinsic pathways. Virology 2011, 409:189-197.
62. Rai C.I., et al. Epitope mapping of dengue-virus-enhancing monoclonal-antibody using phage display peptide library. Am. J. Infect. Dis. 2008, 4:76-84.
63. Pierson T.C., et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007, 135-145.
64. Kuhn R.J., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725.
65. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 2008, 10:e12.
66. Lisova O., et al. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J. Gen. Virol. 2007, 88:2387-2397.
67. Rajamanonmani R., et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J. Gen. Virol. 2009, 90:799-809.
68. Nybakken G.E., et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437:764-769.
69. Thompson B.S., et al. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009, 5:e1000453.
70. Crill W.D., et al. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens 2. PLoS ONE 2009, 4:e4991.
71. Nelson S., et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 2008, 4:e1000060.
72. Wahala W.M., et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392:103-113.
73. Oliphant T., et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 2006, 80:12149-12159.
74. Stiasny K., et al. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 2006, 80:9557-9568.
75. Rodenhuis-Zybert I.A., et al. Immature dengue virus: a veiled pathogen?. PLoS Pathog. 2010, 6:e1000718.
76. Huang K.J., et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 2006, 176:2825-2832.
77. Brien J.D., et al. Genotype-specific neutralization and protection by antibodies against dengue virus type. J. Virol. 2010, 84:10630-10643.
78. Zhang Y., et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004, 12:1607-1618.